Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level

European Journal of Pharmacology

Volumn 371, Issue 2-3, 1999, Pages 153-158

  Hertel, Peter ^a   Nomikos, George G ^a   Svensson, Torgny H ^a  

^a Sect Neuropsychopharmacology   (Sweden)

Author keywords

2 Adrenoceptor; Dopamine extracellular; Idazoxan; Microdialysis dual probe

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; DOPAMINE; IDAZOXAN; TETRODOTOXIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; INTRACEREBRAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NERVE ENDING; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VENTRAL TEGMENTUM;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BRAIN; DOPAMINE; DRUG INTERACTIONS; IDAZOXAN; INJECTIONS, SUBCUTANEOUS; MALE; MICRODIALYSIS; NERVE ENDINGS; NUCLEUS ACCUMBENS; PERFUSION; PREFRONTAL CORTEX; RATS; TETRODOTOXIN; VISUAL CORTEX;

EID: 0032957212     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00175-2     Document Type: Article

References (25)

1. Brozoski T.J., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 205:1979;929-932.
2. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55:1990;1067-1070.
3. Davis R., Wilde M.I. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 5:1996;389-402.
4. Dennis T., L'Heureux R., Carter C., Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmacol. Exp. Ther. 241:1987;642-649.
5. Gobert A., Rivet J.M., Audinot V., NewmanTancredi A., Cistarelli L., Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience. 84:1998;413-429.
6. Grenhoff J., Svensson T.H. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur. J. Pharmacol. 165:1989;11-18.
7. Gresch P.J., Sved A.F., Zigmond M.J., Finlay J.M. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem. 65:1995;111-116.
8. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology. 124:1996;74-86.
9. 2 adrenoceptor antagonism. Neuropsychopharmacology. 17:1997;44-55.
10. Litman R.E., Su T.P., Potter W.Z., Hong W.W., Pickar D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia: comparison with the atypical neuroleptic, clozapine. Br. J. Psychiat. 168:1996;571-579.
11. Matsumoto M., Yoshioka M., Togashi H., Mori K., Ueno K., Saito H. Effects of idazoxan on dopamine release in the prefrontal cortex of freely moving rats. Eur. J. Pharmacol. 343:1998;165-170.
12. 2 adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J. Psychoparmacol. 8:1994;193-195.
13. Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney.
14. Pozzi L., Invernizzi R., Cervo L., Vallebuona F., Samanin R. Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J. Neurochem. 63:1994;195-200.
15. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 71:1994;515-528.
16. 2-adrenoceptor autoregulation of noradrenaline release in rat nucleus accumbens slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1998;87-90.
17. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
18. 2 antagonism. In: Vanhoutte, P.M., Saxena, P.R., Paoletti, R., Brunello, N., Jackson, A.S. (Eds.), Serotonin. Kluwer Academic Publisher and Fondazione Lorenzini, Dordrecht and Milan, pp. 263-270.
19. 2A-adrenergic receptor-like immunoreactivity in the rat central nervous system. J. Comp. Neurol. 372:1996;111-134.
20. Tanda G., Bassareo V., Di Chiara G. Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat. Psychopharmacology. 123:1996;127-130.
21. 2-adrenoceptors of endogenous noradrenaline and dopamine release from slices of rat hypothalamus. Life Sci. 33:1983;371-376.
22. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. 367:1971;1-48.
23. Van Dorth R.M. Review of clinical studies with mianserin. Acta Psychiatr. Scand. 302:1983;72-80.
24. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry. 44:1987;660-669.
25. Yamamoto B.K., Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J. Neurochem. 71:1998;274-280.